{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:27:59Z","timestamp":1789504079083,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merz Aesthetics GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Two randomized, double-blind, placebo-controlled, Phase III studies of incobotulinumtoxinA for treating upper facial lines (UFLs; ie, a combination of glabellar frown lines [GFLs], horizontal forehead lines [HFLs], and lateral canthal lines [LCLs]) were conducted in the United States (ULTRA I: NCT04594213) and Germany (ULTRA II: NCT04622254).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the safety and efficacy of simultaneous intramuscular injections for UFLs. Longer-term safety and efficacy were assessed in open-label extension periods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Healthy participants (\u226518 years) with moderate-to-severe GFLs, HFLs, and symmetric LCLs at maximum contraction on the 5-point Merz Aesthetics Scales were randomized 2:1:1 to receive up to 64 units of incobotulinumtoxinA in the main period for each trial. Treatment groups were: UFLs, GFLs, and HFLs (ULTRA I), LCLs (ULTRA II), and placebo. Primary efficacy endpoints were the proportions of GFL, HFL, and LCL responders, defined as a Merz Aesthetics Scale score for the respective area of 0 (no) or 1 (mild) and a \u22652-grade improvement from baseline to Day 30, as assessed by both investigator and participant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 362 and 368 participants received treatment in ULTRA I and ULTRA II, respectively. In both studies, incobotulinumtoxinA treatment was significantly more effective than placebo with respect to the primary endpoints (P &amp;lt; .0001) and key secondary endpoints (P &amp;lt; .0001). The open-label extension period results were consistent with those seen in the main period. No new safety findings were identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In ULTRA I and ULTRA II, the safety and efficacy of incobotulinumtoxinA for the simultaneous treatment of moderate-to-severe UFLs were demonstrated, with significant improvements across all primary and secondary endpoints vs placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Level of Evidence: 1 (Therapeutic)<\/jats:title>\n                  <jats:p\/>\n               <\/jats:sec>","DOI":"10.1093\/asj\/sjae222","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T12:05:56Z","timestamp":1730289956000},"page":"293-304","source":"Crossref","is-referenced-by-count":9,"title":["IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies"],"prefix":"10.1093","volume":"45","author":[{"given":"John","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sudimac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Mersmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kerscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2025021817444022100_sjae222-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/asj\/sjad354","article-title":"Aesthetic Plastic Surgery National Databank Statistics 2022","volume":"43","author":"The Aesthetic Society","year":"2023","journal-title":"Aesthet Surg J"},{"key":"2025021817444022100_sjae222-B2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/dss.0000000000001277","article-title":"Botulinum toxin in aesthetic medicine: myths and realities","volume":"44","author":"Dover","year":"2018","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B3","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaad.2009.01.005","article-title":"A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy","volume":"60","author":"Carruthers","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2025021817444022100_sjae222-B4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jaad.2009.01.005","article-title":"A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients\u2019 perception of treatment outcomes","volume":"8","author":"Carruthers","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"2025021817444022100_sjae222-B5","first-page":"43","article-title":"Duration of action of abobotulinumtoxina and onabotulinumtoxina: a randomized, double-blind study using a contralateral frontalis model","volume":"4","author":"Nestor","year":"2011","journal-title":"J Clin Aesthet Dermatol"},{"key":"2025021817444022100_sjae222-B6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/archfacial.2011.37","article-title":"An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA","volume":"13","author":"Nettar","year":"2011","journal-title":"Arch Facial Plast Surg"},{"key":"2025021817444022100_sjae222-B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/cpaa.S37582","article-title":"Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines","volume":"5","author":"Prager","year":"2013","journal-title":"Clin Pharmacol"},{"key":"2025021817444022100_sjae222-B8","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/j.1524-4725.2010.01798.x","article-title":"Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study","volume":"36","author":"Prager","year":"2010","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1468-2494.2012.00741.x","article-title":"Exploring the effects of non-medical versus medical approaches to the management of skin aging in women over sixty","volume":"34","author":"Tamburic","year":"2012","journal-title":"Int J Cosmet Sci"},{"key":"2025021817444022100_sjae222-B10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/ddg.12195","article-title":"S1 guideline aesthetic botulinum toxin therapy","volume":"11","author":"Imhof","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025021817444022100_sjae222-B11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.tox.2013.02.006","article-title":"Botulinum toxins: mechanisms of action, antinociception and clinical applications","volume":"306","author":"Wheeler","year":"2013","journal-title":"Toxicology"},{"key":"2025021817444022100_sjae222-B12","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1073\/pnas.1222139110","article-title":"Molecular assembly of botulinum neurotoxin progenitor complexes","volume":"110","author":"Benefield","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025021817444022100_sjae222-B13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/ccid.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025021817444022100_sjae222-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","article-title":"Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products","volume":"15","author":"Frevert","year":"2015","journal-title":"Drugs R D"},{"key":"2025021817444022100_sjae222-B15","author":"European Medicines Agency"},{"key":"2025021817444022100_sjae222-B16","author":"Food and Drug Administration"},{"key":"2025021817444022100_sjae222-B17","author":"Health Canada"},{"key":"2025021817444022100_sjae222-B18","author":"Pharmaceuticals and Medical Devices Agency"},{"key":"2025021817444022100_sjae222-B19","author":"Electronic Medicines Compendium"},{"key":"2025021817444022100_sjae222-B20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1097\/DSS.0000000000000450","article-title":"Efficacy and safety of IncobotulinumtoxinA in the treatment of upper facial lines: results from a randomized, double-blind, placebo-controlled, phase III study","volume":"41","author":"Kerscher","year":"2015","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-88-470-5361-8_3","volume-title":"Injections in Aesthetic Medicine: Atlas of Full-Face and Full-Body Treatment","author":"Stella","year":"2014"},{"key":"2025021817444022100_sjae222-B22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1524-4725.2011.02248.x","article-title":"Validated assessment scales for the upper face","volume":"38","author":"Flynn","year":"2012","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/dsu.12100","article-title":"Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines","volume":"39","author":"Carruthers","year":"2013","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-031-36266-8_6","volume-title":"Image-Guided Aesthetic Treatments","author":"Haney","year":"2023"},{"key":"2025021817444022100_sjae222-B25","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.1097\/dss.0000000000001416","article-title":"Incobotulinumtoxina is an effective and well-tolerated treatment for upper facial lines: results from an open-label extension period of a phase III study","volume":"43","author":"Trevidic","year":"2017","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2019.06.1313","article-title":"Daxibotulinumtoxina for injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)","volume":"82","author":"Bertucci","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025021817444022100_sjae222-B27","doi-asserted-by":"publisher","first-page":"e32375","DOI":"10.1097\/md.0000000000032375","article-title":"Treatment of glabellar lines with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Carruthers","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"2025021817444022100_sjae222-B28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.36849\/jdd.2020.5454","article-title":"Incobotulinumtoxina demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar lines","volume":"19","author":"Kerscher","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"2025021817444022100_sjae222-B29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.36849\/jdd.6377","article-title":"Incobotulinumtoxina demonstrates safety and prolonged duration of effect in a dose-ranging study for glabellar Lines","volume":"20","author":"Kerscher","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"2025021817444022100_sjae222-B30","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1097\/dss.0000000000001295","article-title":"Efficacy of IncobotulinumtoxinA for the treatment of glabellar frown lines in male subjects: post-hoc analyses from randomized, double-blind pivotal studies","volume":"43","author":"Jones","year":"2017","journal-title":"Dermatol Surg"},{"key":"2025021817444022100_sjae222-B31","doi-asserted-by":"publisher","first-page":"651e","DOI":"10.1097\/01.prs.0000480007","article-title":"FACE-Q satisfaction with appearance scores from close to 1000 facial aesthetic patients","volume":"137","author":"Klassen","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"2025021817444022100_sjae222-B32","author":"Food and Drug Administration"}],"container-title":["Aesthetic Surgery Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asj\/advance-article-pdf\/doi\/10.1093\/asj\/sjae222\/61201769\/sjae222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/3\/293\/61201769\/sjae222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asj\/article-pdf\/45\/3\/293\/61201769\/sjae222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:45:20Z","timestamp":1739900720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asj\/article\/45\/3\/293\/7850851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,30]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/asj\/sjae222","relation":{},"ISSN":["1090-820X","1527-330X"],"issn-type":[{"value":"1090-820X","type":"print"},{"value":"1527-330X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,30]]}}}